Potential drug interactions with cannabis-based medicinal products

Author: Shannen Stevens
Category: Medication News, Medication Updates
Date: February 8, 2019

A new document from the UK Medicine Information Service alerts us to the fact that THC and cannabidiol act as enzyme inhibitors at the CYP2C and CYP3A4 isoenzymes. Although cannabinoids are unlikely to be prescribed widely, prescribers and healthcare professionals should be aware that this action may potentiate the effects of CNS-depressant drugs. There is also a potential risk of bleeding, through inhibited platelet aggregation.

You can read the full document on the Specialist Pharmacy Service website.

 

Related Posts